Meyer-Schwesinger C, Dehde S, von Ruffer C, Gatzemeier S, Klug P, Wenzel UO, Stahl RAK, Thaiss F, Meyer TN. Rho kinase inhibition attenuates LPS-induced renal failure in mice in part by attenuation of NF-B p65 signaling. Am J Physiol Renal Physiol 296: F1088 -F1099, 2009. First published February 18, 2009 doi:10.1152/ajprenal.90746.2008.-Rho kinase signaling regulates inflammatory cell migration and chemokine production. We therefore investigated the mechanisms of Rho-kinase-dependent inflammation in lipopolysaccharide (LPS)-induced renal failure. C57/ BL6 mice received intraperitoneal LPS with or without daily treatment with specific Rho kinase inhibitors (Y-27632 or HA-1077; 5 mg/kg). Rho kinase inhibitors were applied in a preventive (12 or 1 h before LPS) or a therapeutic (6 h after LPS) scheme. Both protected renal function and decreased tubular injury in LPS-treated mice. Enhanced Rho kinase activity was inhibited by HA-1077 in capillary endothelial cells, inflammatory cells, and tubuli by analysis of Rho kinase substrate phosphorylation. Early neutrophil influx was reduced by HA-1077 without reduction of the proinflammatory cytokine TNF␣. In contrast, HA-1077 decreased the influx of monocytes/ macrophages coinciding with reduced expression of the NF-Bregulated chemokines CCL5 and CCL2. We therefore examined NF-B signal transduction and found that NF-B p65 phosphorylation and nuclear translocation were reduced by Rho kinase inhibition. IB␣ degradation was not altered during the first 6 h but was reduced by HA-1077 at later time points. NF-B p50-deficient mice were similarly protected from renal injury by Rho kinase inhibition further supporting the prominent role for p65 in Rho kinase inhibition. Together, these data suggest that Rho kinase inhibition by preventive or therapeutic treatment effectively reduced endotoxic kidney injury in part by attenuation of NF-B p65 activation. lipopolysaccharide; nephritis; nuclear factor-B GRAM-NEGATIVE INFECTION and subsequent multiple organ failure remain a significant cause of morbidity and mortality in humans. Lipopolysaccharide (LPS) is a major pathogenic factor during inflammation with gram-negative bacteria. LPS-induced inflammation has been extensively studied in the kidney in an in vivo mouse model of acute, reversible renal failure. In this model, LPS reproducibly induces tubular epithelial cell injury together with leukocyte influx. At present, the mechanisms leading to LPS-induced tubular injury are imperfectly understood and strategies for therapy are lacking for acute renal failure in LPS-induced sepsis in humans.
GRAM-NEGATIVE INFECTION and subsequent multiple organ failure remain a significant cause of morbidity and mortality in humans. Lipopolysaccharide (LPS) is a major pathogenic factor during inflammation with gram-negative bacteria. LPS-induced inflammation has been extensively studied in the kidney in an in vivo mouse model of acute, reversible renal failure. In this model, LPS reproducibly induces tubular epithelial cell injury together with leukocyte influx. At present, the mechanisms leading to LPS-induced tubular injury are imperfectly understood and strategies for therapy are lacking for acute renal failure in LPS-induced sepsis in humans.
LPS-induced inflammatory cytokine gene transcription is mostly mediated via Toll-like receptor 4 and downstream intracellular signaling that leads to activation and nuclear translocation of the NF-B heterodimers composed of p65 and p50 subunits. Both subunits interact with an inhibitor of NF-B (IB␣, -␤, -ε, and -) proteins in the inactive form. Upon stimulation, IBs are phosphorylated at serine residues by IKK␣ and -␤ protein kinases (17) targeting IBs for ubiquitination and degradation by the 26S proteasome. Posttranslational modifications of p65 such as phosphorylation and acetylation can influence activation and transcriptional activity (45) . LPS signaling promotes phosphorylation of p65 at Ser 276 and Ser 536 by IKK␤. The LPS-induced phosphorylation of p65 at Ser 536 increases NF-B-driven transcriptional activity (40) , also independent of IB␣ degradation (41) .
LPS upregulates chemokines in resident kidney cells that attract macrophages and T cells to the interstitium (6) . Three chemokines have been of particular interest in this setting: 1) monocyte chemoattractant protein-1 (CCL2), a chemokine produced by mesangial cells (37) and proximal tubule cells (59) with potent chemotactic activity toward monocytes/macrophages and T lymphocytes (8, 24) ; 2) CCL5 (regulated on activation normal T-cell expressed and secreted; Ref. 32) , with potent chemotactic activity stimulating macrophage, granulocyte, and T-lymphocyte migration into the kidney (44) ; and 3) IFN-␥-inducible protein-10 (CXCL10) expression, which is induced by LPS in glomerular mesangial cells attracting T cells to the glomerulus (14) and in endothelial capillaries of the kidney (29) . CCL5 and CCL2 but not CXCL10 expression is mediated by the transcription factor NF-B in the kidney (35, 37, 38, 59, 62) .
Rho/Rho kinases are involved in NF-B activation (27, 34) , suggesting a potential role of RhoA/Rho kinase in LPS-induced inflammation. Rho kinases are known to act as molecular switches controlling several critical cellular functions, such as actin cytoskeleton organization, cell migration and adhesion, reactive oxygen species formation, and apoptosis (10, 36) . Rho kinases 1/␤ and 2/␣ (Rho-associated kinases/ ROK/ROCK) are serine/threonine protein kinases with 64% of the amino acid sequence homology (90% in the kinase domain) and ubiquitous distribution (3) . The Rho kinase inhibitors HA-1077 (fasudil, 5-isoquinolinesulfonyl-homopiperazine) and Y-27632 [(R)-(ϩ)-trans-N-(4-pyridyl)-4-(1-aminoethyl)-cyclohexanecarboxamide] inhibit Rho kinase potently and specifically (28, 42, 55) . Studies with these inhibitors demonstrated strong antiinflammatory effects. Rho kinase inhibition has been shown to be effective against reperfusion injury of the liver (48) and heart (5), renal tissue fibrosis (16, 31) , cerebral ischemia (43) , and pulmonary hypertension (1) . The anti-inflammatory effect was mediated, at least in part, by reduced NF-B activation (46) . The effect of Rho kinase inhibition on NF-B signaling is a marked reduction of proinflammatory cytokine and chemokine production. TNF-␣, IL-1␤, IL-6, IL-8, and CCL2 cytokine expression was reduced by Rho kinase inhibition in various settings (5, 13, 46, 47, 53) . One consequence of reduced cytokine production is a decrease of leukocyte activation and infiltration into inflamed tissue. Accordingly, Y-27632 reduced leukocyte infiltration in several models of inflammation such as Crohn's disease (46) , atherosclerotic lesions (26) , ischemic heart injury (5), endotoxic liver (53) , and lung injury (52) . In addition to chemokine production, endothelial leukocyte transmigration requires Rho kinase activity for cytoskeletal rearrangement in both the penetrating leukocyte and the permissive endothelial cell (30, 39) . Rho kinases increase myosin light chain (MLC) phosphorylation on Ser 19 via inhibition of the regulatory subunit of the myosin-specific phosphatase, and inhibition of the Rho-Rho-kinase pathway decreases MLC phosphorylation and actin stress fiber formation (28, 55) and thereby abolishes the ability for cytoskeletal rearrangement. In consequence, LPS induces endothelial cell contraction via Rho-kinase-dependent inactivation of MLC phosphatase and increases vascular permeability for leukocytes (11) .
Given these strong data in support of a protective role for Rho kinase inhibition in LPS-induced inflammation, we examined the effects of a preventive and therapeutical application of the Rho kinase inhibitors HA-1077 and Y-27632 on renal function, leukocyte recruitment, chemokine expression, and NF-B signaling in the kidney of LPS-treated mice.
MATERIALS AND METHODS
Animal care. Wild-type male C57BL/6 mice (Charles River) and C57BL/6 NF-B p50 Ϫ/Ϫ mice (B6;129P2-Nfkb1 tm1Bal /J; Jackson Laboratory) were bred in house under flow sterile conditions. Mice had free access to water and standard animal chow. The animal experiments were performed according to National and Institutional Animal Care and Ethical Guidelines and were approved by the Veterinarian Agency of Hamburg and the local animal Care committee.
Induction of LPS nephritis. In five separate experiments with a total of 269 mice (n ϭ 3-5 for each condition and time point, 25-30 g body wt, 12-14 wk old) were given an intraperitoneal injection of 3 mg/kg body wt LPS (E. coli. O111:B4; Sigma, Hamburg, Germany) or sterile H 2O. For experiments with NF-B p50 mice, male control or male NF-B p50 Ϫ/Ϫ mice were given an intraperitoneal injection of 1.5 mg/kg body wt LPS or sterile H2O. Urine was collected in metabolic cages 1, 3, 6, 12, 24, 48 , and 72 h after induction of the disease. Mice were weighed and killed while they were under anesthesia with isoflurane at 1, 3, 6, 12, 24, 48, and 72 h by cervical neck dislocation. After the collection of blood, kidneys were cut into equal pieces for the isolation of mRNA, protein, and histology.
Rho kinase inhibition. Rho kinase was inhibited with two wellestablished Rho kinase inhibitors, HA-1077 and Y-27632. Both inhibitors were applied at 10 g⅐g mouse Ϫ1 ⅐24 h Ϫ1 by intraperitoneal injection. Three different time courses were investigated ( Fig. 1A) : 1) application of HA-1077 beginning 12 h before injection of LPS; 2) application of Y-27632 1 h before injection of LPS; and 3) application of HA-1077 6 h after injection of LPS.
Blood pressure measurement. Systolic blood pressure was measured using tail-cuff impedance plethysmography (TSE Systems, Bad Homburg, Germany) in trained mice for 5-10 min without anesthesia as described before. Blood pressure measurements were performed in control mice, LPS-treated mice, and LPS mice pretreated with HA-1077 (n ϭ 5 for each condition).
Periodic acid-Schiff and renal histology score. Renal tissue injury was assessed in paraffin-embedded (Medim Histotechnologie, Buseck, Germany) and paraformaldehyde (4%)-fixed tissue sections stained by the periodic acid-Schiff reaction. A semiquantitative score for tubular injury and for acute tubular necrosis was calculated for each animal by a double-blinded observer as described before (58) . The percentages of tubules that displayed cellular necrosis, loss of brush border, interstitial edema, vacuolization, and tubule dilation were scored as follows: 0 ϭ none, 1 ϭ Ͻ30%, 2 ϭ 30 -60%, and 3 ϭ Ͼ60%. For each animal, at least 10 high-power fields were examined (ϫ200).
Immunohistochemistry. 19 , 0.05% citraconic anhydride pH 7.4). Unspecific binding was blocked with 5% normal horse or goat serum (Vector, Burlingame, VT) for 30 min at room temperature. Primary antibody incubations were performed in 5% normal horse or goat serum overnight at 4°C, followed by incubation with biotinylated affinity purified donkey secondary antibodies (1:400; all Jackson ImmunoResearch Europe, Newmarket, UK). Color development was performed with the ABC-AP kit (Vector) according to the manufacturer's instructions. Neufuchsin was used as substrate for alkaline phosphatase (Merck, Darmstadt, Germany), and nuclei were counterstained with hematoxylin (Merck) for light microscopic evaluation. Stainings were evaluated under an Axioskop (Zeiss, Jena, Germany) and photographed with an Axiocam HRc (Zeiss) using the Axiostar software (Zeiss).
Inflammatory cell influx. All inflammatory cells were counted in a double-blinded fashion. The following conditions were counted: highdose LPS application: control, control Ϫ1-h Y-27632, control Ϫ12-h HA-1077, LPS, LPS Ϫ1-h Y-27632, LPS Ϫ12-h HA-1077, and LPS ϩ 6-h HA-1077; and for low dose LPS application: control, LPS, LPS ϩ 6-h HA-1077, p50
Ϫ/Ϫ control, p50 Ϫ/Ϫ LPS, and p50 Ϫ/Ϫ LPS ϩ 6-h HA-1077. CD3-positive T cells were counted in 10 low power visual fields (200-fold magnification) for n ϭ 3 mice per time point (0, 1, 3, 6, 12, 24, 48, and 72 h) and condition. For quantification of F4/80-positive monocytes/macrophages and neutrophils, 10 high power visual fields (400-fold magnification) for 3 mice per time point and condition were counted. Values are expressed as ϮSE.
Serum urea nitrogen and serum and urine creatinine. Serum creatinine, serum urea, and urine creatinine were determined by standard methods using an autoanalyzer (Hitachi 717; Roche, Mannheim, Germany) in the Department of Clinical Chemistry at the University Hospital Hamburg.
Immunoblot. Lysates were obtained by lysis of 10 mg of kidney tissue with 100 l of T-PER lysis buffer (Pierce, Bonn, Germany) containing a cocktail of phosphatase inhibitors. For immunoblotting of Rho kinase 1 (1:1,000; Transduction Laboratories), Rho kinase 2 (1:1,000; Transduction Laboratories), phospho-myosin phosphatase target subunit 1 (phosphor-MYPT1; 1:1,000; Cell Signaling), phospho-ERM (1:1,000; Cell Signaling), ezrin (1:2,000; Sigma), p65 and Ser 536 phosphorylated p65 (1:1,000; Cell Signaling; rabbit mAB), IB␣ (1:1,000; Cell Signaling), or ␤-actin (1:3,000; Sigma) as loading control, lysates were centrifuged for 15 min at 10,000 g and supernatant was denatured with 4ϫ lithium dodecyl sulfate sample buffer. Samples were separated on a 4 -12% Bis-Tris NuPage gel (Invitrogen, Karlsruhe, Germany) in NuPage running buffer (MOPS; Invitrogen) for 1 h at 60 mA. Protein transfer to an activated PVDF membrane (Millipore, Eschborn, Germany) was performed in transfer buffer (50 mM Tris base and 0.192 M glycine in ddH2O) in a Novex Mini Cell (Invitrogen) for 1 h at 30 V and 4°C. The PVDF membranes were blocked in 3% nonfat milk or with Superblock blocking reagent (Pierce) for 60 min before incubation with the primary antibody diluted in Superblock blocking reagent. The primary antibody was removed by being washed in Tris-buffered saline-Tween for 40 min and detected by incubation for 1 h with horseradish peroxidase (HRP) coupled secondary anti-mouse antibody (Jackson ImmunoResearch) diluted 1:10,000 in 3% nonfat milk. After being washed in Trisbuffered saline-Tween for 40 min, proteins were visualized with ECL SuperSignal (Pierce) according to the manufacturer's instructions on a Biomax Light Film (Kodak). Immunoblots were analyzed using software from ImageJ (2).
Quantitative PCR. Total RNA from whole kidney slices of each mouse was prepared as described previously (49) and reverse-transcribed (Superscript II; Invitrogen) by the use of random hexamer primers (Invitrogen, Karlsruhe, Germany). mRNA expression was quantified with an AbiPrism NN8650 using SYBR green as previously described (33) . The used primers were exon spanning the following: TNF␣ (forward: 3Ј-aaatggcctccctctcatcagt-5Ј; reverse: 3Ј-gcttgtcactcgaattttgagaag-5Ј), CCL2 (forward: 3Ј-ggctcagccagatgcagttaa-5Ј; reverse: 3Ј-cctactcattgggatcatcttgct-5Ј), CXCL10 (forward: 3Ј-gccgtcattttctgcctcat-5Ј; reverse: 3Ј-tgcagcggaccgtcctt-5Ј), CCL5 (forward: 3Ј-gcaagtgctccaatcttgca-5Ј; reverse: 3Ј-cttctctgggttggcacaca-5Ј), Rho kinase 1 (forward: 3Ј-caaacgtcatctcttcttcaaaaatg-5Ј; reverse: 3Ј-aatgtcactacttaaatcaggcacaact-5Ј), Rho kinase 2 (forward: 3Ј-aattcactgtgttttcctgaagataca-5Ј; reverse: 3Ј-accccatttcttccaagtcgta-5Ј), and 18S primers (forward: 3Ј-cacggccggtacagtgaaac-5Ј; reverse: 3Ј-agaggagcgagcgaccaaa-5Ј), and they were used as an internal control to correct for small variations in RNA quality and cDNA synthesis essentially as described by AbiPrism. Amplicons of random samples for each primer pair were determined by automatic DNA sequencing to demonstrate the specifity of the PCR reaction (data not shown). Relative quantification of gene expression was calculated using the ⌬⌬CT method.
Myeloperoxidase assay. Myeloperoxidase (MPO) levels were measured in protein lysates of LPS mice and Rho-kinase-inhibited LPS mice by ELISA according to procedures recommended by the manufacturer (Calbiochem, Darmstadt, Germany).
Nuclear fractionation. Nuclear and cytoplasmic extracts were isolated from whole kidneys of freshly killed mice using the NE-Per kit (Pierce) according to the manufacturer's instructions. Kidneys from experimental groups were pooled (n ϭ 3 mice per group).
Total Rho kinase activation assay. For measurement of total Rho kinase activity, the whole kidney was lysed in T-Per (Pierce) according to the manufacturer's instructions. For the activity assay, 500 ng MYPT1 (654 -880; Upstate Biotechnology, Lake Placid, NY) and Tris/ATP (final concentration: 1 mM ATP, 50 mM Tris ⅐ HCl, 0.1 mM EGTA, 0.1 M DTT, and 10 mM MgCl 2) were added to the lysates, and recombinant Rho kinase 2 protein (MBL, Woburn, MA) was added for the positive control. The lysates were incubated for 30 min at 30°C. The reaction was stopped by adding 4ϫ lithium dodecyl sulfate and by subsequent heating of the assays for 10 min at 72°C. Phosphorylation of MYPT1 by Rho kinase was detected by running the assays on a SDS PAGE and by subsequent immunoblotting with an anti phospho-MYPT1 (Thr 850 ; Upstate) 1:5,000 in 3% nonfat milk followed by the secondary antibody anti rabbit HRP (1:15,000; Jackson Immunoresearch Laboratories) in 3% nonfat milk. As a loading control, internal MYPT1 was detected by immunoblotting with an anti-MYPT1 (BD Biosciences, Heidelberg, Germany) followed by the secondary antibody anti-mouse HRP (1:15,000; Jackson Immunoresearch Laboratories) in 5% nonfat milk.
Rho kinase 1 and 2 activation assay. For measurement of isoformspecific Rho kinase activity, the whole kidney was lysed in T-Per (Pierce) according to the manufacturer's instructions. Lysates were precleared with protein G agarose for 30 min at 4°C. Rho kinase 1 and Rho kinase 2 antibodies coupled to protein G (10 l of Rho kinase 1 and 0.25 g/l of Rho kinase 2; both from Santa Cruz) or 0.5 l goat IgG (11 g/l) as a negative control for 45 min at 4°C. Rho kinase 1 and 2 were immunoprecipitated for 1 h at 4°C from precleared lysates. Activity assays were performed as for total Rho kinase activity assays (described above) with 500 ng MYPT1 and Tris/ATP. Recombinant Rho kinase 2 protein was added for the positive control. Phosphorylation of MYPT1 by immunoprecipitated Rho kinase was detected by running the assays on a SDS PAGE and by subsequent immunoblotting with an anti phospho-MYPT1. Internal MYPT1 as a loading control was detected by immunoblotting with an anti MYPT1.
Statistics. Values are means Ϯ SE; n refers to the number of animals or individual measurements in separate samples. Differences between multiple experimental groups were compared by KruskalWallis analysis with post hoc analysis by the Mann-Whitney U-test. Paired Student's t-test was used to compare mean values within one experimental series. A P value of Ͻ0.05 was accepted as statistically significant.
RESULTS

LPS-induced renal failure is abolished by Rho kinase inhibition.
Mice were killed after 0, 1, 3, 6, 12, 24, 48, and 72 h after administration of LPS, and kidneys were evaluated by histology (periodic acid Schiff). All control mice treated with saline (Fig. 1B, a) , HA-1077 (Fig. 1B, b) , or Y-27632 only (not shown) demonstrated a normal histology. In LPS-treated mice, predominantly interstitial disease was observed (Fig. 1B, c) . Interstitial disease was less in all Rho-kinase-inhibited mice and was evaluated using a renal histology score described before (58) . LPS-treated mice showed more severe interstitial damage along the time course of 72 h compared with HA-1077 (Ϫ12 h) pretreated or (ϩ6 h) posttreated (Fig. 1C) or with Y-27632-treated mice (not shown). Within the obstructed tubuli, tubular epithelial cells were swollen and vacuolated. Blood pressure was not different in LPS vs. LPS ϩ HA-1077-treated mice. LPS and LPS ϩ HA (Ϫ12 h) groups showed a similar drop in blood pressure at 3, 6, and 9 h with recovery to normal blood pressure at 12 h (Fig. 1D) . Importantly, the application of HA-1077 alone did not lower blood pressure, most likely because of the low dose applied. Clinically, serum urea nitrogen was significantly increased at 12 and 24 h in LPS-treated mice. Preincubation with HA-1077 (Fig. 1E) or Y-27632 (Fig. 1F) prevented the increase, resulting in serum urea nitrogen values slightly above normal. However, even the application of HA-1077 6 h after injection of LPS was able to almost completely abolish the rise in serum urea nitrogen. These data indicated that Rho kinase activation is an important mediator of renal injury during LPS-induced renal failure.
Rho kinase is activated and application of Rho kinase inhibitors decrease Rho kinase activity during LPS-induced renal failure.
To examine the effect of Rho kinase on LPSinduced renal failure, we first determined Rho kinase protein and mRNA expression. Rho kinase 2 showed an initial, nonsignificant, decrease with subsequent increase in protein content ( Fig. 2A) . However, Rho kinase 2 mRNA expression was increased significantly at 12 and 24 h (Fig. 2B) . In contrast, Rho kinase 1 protein and mRNA did not change throughout the time course. Total Rho kinase activity was measured along the time course in whole kidney lysates with a Rho kinase activation assay using the Rho-kinase-specific effector target on MYPT1. Rho kinase activity increased immediately after LPS application and reached a maximum 24 h after LPS application (Fig. 2C) . Pretreatment with HA-1077 prevented activation of Rho kinases throughout the time course, and posttreatment with HA-1077 significantly decreased maximum Rho kinase activity. To assess which Rho kinase isoform was predominantly involved in LPS-induced renal failure, the isoformspecific Rho kinase activity was measured (Fig. 2D ) using a target bound Rho kinase assay as described in MATERIALS AND METHODS. Rho kinase 2 activity was significantly increased 12 h after LPS application, whereas Rho kinase 1 activity was not.
Localization of Rho kinase activity was analyzed by immunohistochemical staining for Rho-kinase-specific phosphorylation sites on the substrate ERM and the phosphorylation of MLC on Ser 19 . LPS caused massive phosphorylation of MLC on Ser 19 in tubular segments mostly representing distal tubules 3 h after injection (Fig. 3A, c) and in capillary endothelial cells (Fig. 3, insets) . Six hours after LPS nephritis induction, most glomeruli also stained strongly positive for phosphorylated MLC in podocytes and glomerular endothelial cells (Fig. 3A,  d) . MLC phosphorylation declined thereafter but was detectable 24 h after induction (Fig. 3A, e and f) . In contrast, Rho-kinase-inhibited mice showed reduced MLC phosphorylation after a 12-h preincubation (Fig. 3A, g ) and only limited MLC phosphorylation along the time course (Fig. 3A, h-l) . Application of HA-1077 6 h after LPS was similarly able to reduce tubular and endothelial MLC phosphorylation at the 12-and 24-h time points (Fig. 3C, m and n) .
Similar results were obtained by analyzing the phosphorylation of ERM, a cytoskeletal Rho kinase substrate (Fig. 3, B  and C) . Phosphorylation of this highly conserved phosphorylation site reflects activation of Rho kinase and was activated in whole kidney lysates in a time course similar to Rho kinase activation. ERM phosphorylation started immediately after LPS application and increased until 12 h before returning to normal values. Pretreatment of LPS mice with HA-1077 abolished the phosphorylation of ERM, and HA-1077 alone significantly lowered phospho-ERM below control values throughout the time course (Fig. 3C) . The application of HA-1077 at 6 h after LPS also reduced ERM phosphorylation quickly and significantly. Therefore, we visualized the phosphorylation of ERM using immunohistochemistry (Fig. 3B) . In LPS-treated mice, phospho-ERM was increased in two specific localizations: first, a distinct signal was obtained on mononuclear cells along the vessel wall, and second, the endothelial lining along all larger and smaller vessels and also the capillary network lining the tubuli showed increased phosphorylation of ERM similar to MLC phosphorylation compared with control (Fig.  3B, a and b) . In Rho-kinase-inhibited mice, this specific phos-phorylation was almost completely abolished (Fig. 3B, c and  d) . This finding is particularly interesting, because both locations are critically involved in the passage of leukocytes into inflamed tissue (30, 39) . We therefore speculated that infiltration of leukocytes, a hallmark of LPS-induced renal damage, would be reduced in Rho-kinase-inhibited mice.
Number of infiltrating leukocytes was significantly reduced in Rho-kinase-inhibited LPS-treated mice.
The number of F4/ 80-positive monocytes/macrophages, CD3-positive T cells, and neutrophils was quantified by immunohistochemistry (Fig. 4 ) in addition to MPO activity as a measure for neutrophil activity. Neutrophil count and MPO activity increased immediately after LPS injection to a maximum at 3 h (neutrophils) and 6 h (MPO activity) before decreasing to normal values (Fig. 4A) . The increase in MPO activity was significantly reduced by HA-1077 pretreatment (Ϫ12 h). Posttreatment (ϩ6 h) had no influence on MPO activity at 12 or 24 h compared with LPS-treated mice. A significant reduction was also observed for interstitial F4/80-positive monocytes/macrophages with pre-and posttreatment (Fig. 4B) . Both treatment schemes decreased F4/80-positive cells in two distinct patterns. Whereas pretreatment significantly decreased the LPS-induced influx of F4/80-positive cells during the early time points (3, 6, and 12 h), posttreatment significantly decreased F4/80-positive cells at later time points (12, 24 , and 48 h). In contrast, Rho kinase inhibition had no statistically significant effect on interstitial T-cell number (Fig. 4B) . Interestingly, at 72 h the number of both CD3-positive T cells and F4/80-positive monocytes/macrophages increased further and this increase was not influenced by Rho kinase inhibition.
Rho kinase inhibition decreased chemokine expression in LPS-treated mice. LPS application induces a strong increase in cytokine expression via activation of Toll-like receptor 4 and the NF-B pathway (22; CCL5 and CCL2) but also via NF-B-independent pathways (CXCL10). We therefore investigated the LPS-induced cytokine response under Rho kinase inhibition by quantitative PCR of whole kidney mRNA (Fig. 5) . The immediate increase of the cytokine TNF␣, which attracts neutrophils to the kidney, was not influenced by pretreatment with HA-1077 (Fig. 5A) . Similarly, the chemokine CXCL10 showed a strong increase at 3 h, which was not attenuated by HA-1077 pretreatment (Fig. 5B) . The application of HA-1077 at ϩ6 h was without effect, since CXCL10 and TNF␣ expression had already returned to baseline when treatment commenced. In contrast, the chemokine CCL5 showed a prolonged increase of expression after LPS injection with maximal expression at 12 h and a return to baseline at 48 h. Rho kinase inhibition by HA-1077 at Ϫ12 or ϩ6 h after LPS injection decreased CCL5 expression strongly (Fig. 5C) . Similarly, Y-27632 applied 1 h before LPS induced a decrease in maximal CCL5 expression (n ϭ 5, not shown). CCL2 expression was increased to maximal expression at 3 h with a rapid decrease to almost normal values at 1 2h. Maximal CCL2 expression was decreased by HA-1077 (Ϫ12 h; Fig. 5D ). However, HA-1077 application at ϩ6 h after LPS injection had no effect because CCL2 had already returned to baseline at 12 h. In summary, only the expression of NF-B-dependent chemokines was reduced by pretreatment with HA-1077 or Y-27632 and only CCL5 expression was affected by posttreatment (ϩ6 h) with HA-1077.
NF-B p65 phosphorylation and nuclear translocation were altered in Rho-kinase-inhibited mice.
To assess the role of Rho kinase inhibition on NF-B p65, we utilized Western blots for p65, p65 phosphorylation, and immunoblots of pooled cytosolic and nuclear fractions. Phosphorylation of the NF-B subunit p65 at Ser 536 occurs during IB-dependent and -independent NF-B-induced transcriptional activation (41) . We therefore evaluated the effect of Rho kinase inhibition on p65 Ser 536 phosphorylation along the time course (Fig. 6A) . p65 Ser 536 phosphorylation was increased immediately after LPS application with a maximum at 12 h. Preincubation with HA-1077 decreased p65 Ser 536 phosphorylation under control conditions and prevented the LPS-induced increase significantly for the first 12 h. In contrast, IB␣ degradation in pretreated and untreated LPS nephritis by immunoblot was similar in both groups during the early time points (1-6 h). LPS reduced IB␣ to an almost undetectable level at 1 h with recovery at 3 h and increased IB␣ protein content at 6 h (Fig. 6B) . HA-1077 pretreatment beginning at Ϫ12 h did not prevent the initial decrease or the subsequent increase in IB␣ protein content after LPS injection. On the contrary, IB␣ protein was found to be significantly increased by HA-1077 at 48 and 72 h. We therefore investigated whether nuclear translocation of p65 was reduced by Rho kinase inhibition independent of IB␣ degradation and followed the time course of p65 content in pooled cytosolic and nuclear fractions ( Fig. 6C; n ϭ 3 mice) . LPSinduced an instant increase in nuclear p65 at 1 h, followed by a slow increase to a maximum at 48 h. Preincubation with HA-1077 (Ϫ12 h) prevented the initial increase completely and lowered nuclear p65 at 1 h. Thereafter, a slow increase of nuclear p65 occurred, which was comparable with the second increase in noninhibited LPS mice. HA-1077 application beginning 6 h after LPS fixed the level of nuclear p65 protein level at the 6 h time point and thus abrogated the second increase in nuclear shift at 48 h observed in untreated LPS mice. Cytosolic p65 decreased initially before increasing from 12 h after LPS injection (Fig. 6C) . HA-1077 (Ϫ12 h) prevented this decrease and allowed only a modest increase 12 h after LPS injection. Again, HA-1077 (ϩ6 h) fixed the cytosolic p65 protein level at the 6-h time point. Calculated nuclear fraction of p65 (i.e., the ratio of nuclear over cytosolic densitometry) revealed a strong initial nuclear translocation of p65 at 1 h after LPS injection with normalization at 24 h. HA-1077 application beginning at Ϫ12 h completely prevented this increase and HA-1077 application beginning at ϩ6 h fixed the nuclear level of p65 at the level of 12 h without allowing a reduction to normal levels. In summary, Rho kinase inhibition prevented nuclear translocation of NFB p65 subunit during the early phase of LPS-induced NF-B activation. Application of HA-1077 after the early phase (ϩ6 h) locked p65 subunit into the compartment, where it was present at that time without allowing normalization or further increase. Immunohistochemistry supported the altered nuclear p65 translocation with pre-and posttreatment observed in immunoblot analysis. Whereas HA-1077-pretreated mice with or without LPS injection showed minimal nuclear p65 staining, LPS-treated mice showed marked nuclear p65 immunostaining in most nuclei at the 12 h time point (not shown). Taken together, these data suggest that treatment of LPS nephritic mice with Rho kinase inhibitors affected the NF-B pathway via inhibition of p65 activation and nuclear translocation.
p50 deletion did not alter the response to Rho kinase inhibition in LPS-treated mice. To determine whether the observed effects of Rho kinase inhibition on NF-B p65 subunit may have been driven by altered signaling of the interacting p50 subunit, homozygous p50 Ϫ/Ϫ mice and C57/ BL6 control mice were treated with LPS. Rho kinase was inhibited 6 h after LPS injection (posttreatment) and the LPS dose was halved to secure survival of p50 Ϫ/Ϫ mice. Interestingly, the LPS-induced histological changes were again markedly reduced by HA-1077 in p50 Ϫ/Ϫ mice and in control mice (Fig. 7A) . Similarly, serum urea nitrogen was reduced in p50 Ϫ/Ϫ and control mice by HA-1077 (Fig. 7B) , and also CCL5 mRNA was reduced by HA-1077 in control and in p50 Ϫ/Ϫ mice (Fig. 7C) . Taken together, the clinical, histological, and inflammatory responses were comparable in p50 Ϫ/Ϫ and wild-type LPS mice with or without HA-1077 posttreatment. Therefore, the beneficial effect of HA-1077 posttreatment in LPS nephritis was not mediated by the NF-B p50 subunit.
DISCUSSION
This study establishes a role for Rho kinases in LPSmediated kidney injury in mice and demonstrates that LPS nephritis could be prevented and treated by inhibition of Rho kinases. Two well-established inhibitors, HA-1077 (9) and Y-27632 (20) , similarly attenuated renal failure. HA-1077 was used for the extensive analysis of chemokine and NF-B signaling in four out of five mouse experiments because of the lower costs. Also, HA-1077 is being evaluated in human clinical trials in cerebral vasospasm and angina pectoris (50, 56) and is therefore the first Rho kinase inhibitor with potential use in human kidney disease. In our mice, the low daily dose of both inhibitors did not affect blood pressure in addition to the decrease of blood pressure by LPS administration alone. Likewise, the protective effects of Rho kinase inhibition in the kidney were related to decreased inflammation rather than blood pressure reduction in hypertensive and fibrotic models of kidney injury (21, 31) .
Two isoforms of Rho kinase have been identified, Rho kinase 1 and Rho kinase 2; however, isoform-specific regulation remains largely unknown. Although both Rho kinases appear to have different activities on the cellular level (61) , gene disruption of the two isoforms in mice resulted in similar phenotypes, suggesting functional redundancy between the two isoforms (36, 54) . Rho kinase 1 deletion caused reduced chemotaktic leukocyte migration into inflamed tissue (57) . However, Rho kinase 2, but not 1, was described to play a dominant role in the regulation of inflammation and fibrosis in the kidney (12) and Rho kinase 2 activity was upregulated by LPS in mesenteric artery in rats (7) . In accordance with these findings, only Rho kinase 2 activity was upregulated after LPS treatment in our mice, suggesting a predominant role for Rho kinase 2 in inflammatory signaling.
The immunohistochemical evaluation of ERM and MLC phosphorylation allowed the localization of increased Rho kinase activity in LPS nephritic vs. healthy mice. Phosphorylation of MLC, which mediates cellular contraction, was strongly upregulated in distal tubules and in peritubular capillaries in a time course similar to the increase in Rho kinase activity. Such Rho kinase-dependent phosphorylation of MLC has been recently described to correlate with tubular contraction in diabetic nephropathy (19) , suggesting contraction as a mechanism for tubular cell cytoskeletal rearrangement and shedding. In accordance with these findings, Rho kinase ameliorated LPS-induced tubular vacuolization and brush border shedding in our model. In addition, increased phosphorylation of the Rho kinase substrate ERM was detected on infiltrating leukocytes and also along the capillary endothelium. The leukocyte uses the cytoskeletal network and Rho-kinase-dependent phosphorylation of proteins such as ezrin for its shape change to invade the endothelial monolayer (30) . Similarly, the endothelial cell changes its shape Rho kinase and ezrin dependent to allow passage of the leukocyte (39) . Therefore, the reduction of ERM phosphorylation in leukocytes and endothelial cells in Rho-kinase-inhibited mice might reflect the reduced ability to infiltrate the kidney, as shown by the reduced number of neutrophils and monocytes/macrophages in our study.
Interestingly, preventive Rho kinase inhibition decreased neutrophil number and activity and monocyte/macrophage influx, whereas no significant effect was observed on T-cell infiltration. Correlating, quantitative PCR analyses demonstrated a reduced chemokine expression of CCL2 at 1 and 3 h and CCL5 at 12 and 24 h but not CXCL10 (which attracts T cells) with preventive Rho kinase inhibition. CCL2 and CCL5 chemokines attract mostly neutrophils and monocytes/macrophages and have been implicated in inflammatory kidney disease and in LPS-induced renal inflammation (15, 60) . Together, these data imply that early neutrophil infiltration may have been decreased by Rho-kinase-inhibited CCL2 expression, whereas later monocyte/macrophage accumulation was reduced by decreased CCL5 expression. Accordingly, in posttreated LPS nephritic animals Rho kinase inhibition had no effect on neutrophils, since neutrophil activation and influx occurred within the first 6 h. However, posttreatment significantly reduced the influx of F4/80-positive monocytes/macrophages together with reduced CCL5 but not CCL2 chemokine expression. These data suggest that CCL5 expression may have been responsible for the prolonged infiltration of monocytes/ macrophages in LPS nephritis. The reduction of tissue damage by HA-1077 posttreatment may therefore be explained by a reduction of monocyte macrophage number and/or by decreased monocyte/macrophage activation by CCL5.
The differential effect of Rho kinase inhibition on several chemokines suggested a specific effect of Rho kinase inhibition on chemokine transcriptional activation. Because both CCL5 and CCL2 are regulated via the NF-B pathway in LPSinduced sepsis (35, 59) , we further investigated NF-B signaling of IB␣ and p50 and p65 subunits in LPS-treated and Rho-kinase-inhibited mice. Depletion of p50 did not prevent the effect of Rho kinase inhibition on LPS-induced inflammation, and nephritis and IB␣ degradation occurred normally during the first 6 h despite preventive inhibition of the Rho kinases. However, p65 phosphorylation at Ser 536 was clearly decreased by HA-1077, suggesting that reduced p65 activation was responsible for the observed effect of Rho kinase inhibition on NF-B signaling. We further investigated p65 nuclear translocation and found that pretreatment with HA-1077 decreased nuclear translocation of p65. Together, these data indicate that Rho kinase inhibition prevented early NF-B activation by reduction of activating phosphorylation at Ser 536 and nuclear translocation in the kidney in our mice. Previous studies have shown that phosphorylation of p65 at Ser 536 conferred LPS-induced NF-B-driven transcriptional activity (40) also independent of IB␣ degradation (41) by increasing the transcriptional activity in the nucleus. Whereas NF-B p65 Ser 536 phosphorylation upon activation was reduced by Y-27632 (4, 26) similar to our findings, this finding was not reproduced by others (10) . Inconclusive data exist about the effect of Rho kinase inhibition on IB␣ degradation. A number of groups reported reduced phosphorylation and degradation of IB␣ by Rho kinase inhibition (4, 26, 46) . However, in our LPS-treated mice IB␣ degradation was not influenced by Rho kinase inhibition during the early time points similar to findings by Hippenstiel et al. (18) .
Strikingly, posttreatment with Rho kinase inhibitor also attenuated tissue damage and decreased CCL5 expression even though early p65 activation had already occurred. The mechanism of this late regulation is not clear but may result from attenuation of NF-B p65 signaling by blockade of further nuclear translocation as shown in our mice. Also, the noted reduction in IB␣ degradation in HA-1077-treated mice during later time points might reflect reduced p65 activation in the cytosol. In addition, several other transcription factors or adaptor proteins are regulated by Rho kinase as reviewed by Krensky and Ahn (23) . One such transcriptional adaptor protein, p300 acetyltransferase, was recently reported to interact with Rho kinase 2 in the nucleus, resulting in activation and increased p300 acetylation (51) . It is therefore possible that Rho kinase 2 activity within the nucleus contributed to the observed transcriptional activity after LPS induced inflammation and that such activity was also inhibited by our Rho kinase inhibitors in our model. New isoform-specific Rho kinase inhibitors such as the selective Rho kinase 2 inhibitor SLx-2119 (Surface Logix, Brighton, MA) or other compounds (reviewed in Ref. 25 ) might be beneficial in the specific setting of inflammatory renal disease as studied in our mice.
In summary, our studies demonstrate for the first time that Rho kinase inhibition attenuated renal injury in LPS-treated mice by decreasing enhanced Rho kinase 2 activity, chemokine production, and leukocyte infiltration. Early NF-B p65 subunit regulation was significantly altered by Rho kinase inhibition together with decreased IB␣ degradation at later time points. Importantly, this is the first study describing renal protection in an inflammatory renal disease by therapeutic intervention in a blood pressure independent way.
